TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11353932
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide (NO) inhalation (20 ppm for 1 hour)
Study: 9398951
Drug: 0.05 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg.kg‐1 rocuronium + 1.5 mg.kg‐1 succinylcholine
Study: 9398951
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline followed by 1.0 mg.kg‐1 succinylcholine
Study: 8435812
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated radiation therapy at 48 Gy
Study: 8435812
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated radiation therapy at 54.4 Gy
Study: 8435812
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated radiation therapy at 64 Gy
Study: 8435812
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated radiation therapy at 70.4 Gy
Study: 26553413
Drug: Endourethral collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endourethral collagen type 2 injection
Study: 26553413
Drug: Endourethral saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endourethral saline water injection
Study: 22648218
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 5%/clindamycin 1% gel (BPO/C)
Study: 22648218
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel (AP)
Study: 17525166
Drug: valdecoxib 20
Normalized name: valdecoxib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valdecoxib 20 mg bid
Study: 17525166
Drug: valdecoxib 40
Normalized name: valdecoxib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valdecoxib 40 mg qd
Study: 15302981
Drug: eprosartan 600
Normalized name: eprosartan 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eprosartan 600 mg
Study: 12049152
Drug: Tofu +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofu + Orange Juice (6 oz tofu + 303 mg vitamin C/day)
Study: 9834279
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg twice daily for 2 weeks
Study: 9834279
Drug: Imipenem 500
Normalized name: imipenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem 500 mg three times daily for 2 weeks
Study: 1777912
Drug: Ionic contrast
Normalized name: IONIC CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic contrast agent
Study: 1777912
Drug: Nonionic contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic contrast agent
Study: 2552740
Drug: 300 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micrograms immune globulin anti-D administered prenatally
Study: 31254681
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at TE3 and TE5 for 30 minutes
Study: 23182627
Drug: Tivantinib (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (360 mg twice‐daily)
Study: 23182627
Drug: Tivantinib (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (240 mg twice‐daily)
Study: 23182627
Drug: Tivantinib 360
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib 360 mg
Study: 23182627
Drug: Tivantinib 240
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib 240 mg
Study: 21817157
Drug: Simultaneous intratympanic
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous intratympanic dexamethasone with systemic steroids
Study: 21817157
Drug: Subsequent intratympanic
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subsequent intratympanic dexamethasone given 7 days after systemic treatment
Study: 21817157
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone treatment
Study: 19118304
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg per day for 3 years
Study: 19118304
Drug: Alendronate (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (various doses)
Study: 19118304
Drug: Alendronate treatment
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate treatment discontinued for 1 year
Study: 7800216
Drug: Cyclosporin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (12 mg/kg)
Study: 8301102
Drug: Cyclosporin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (30 mg/kg)
Study: 24831979
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day, orally)
Study: 24831979
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed 500 mg/m2, intravenously, every 21 days, or docetaxel 75 mg/m2, intravenously, every 21 days)
Study: 8746044
Drug: Short chain
Normalized name: Short chain acyl-CoA dehydrogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short chain fatty acids enema (acetate: 60 mmol/L; propionate: 30 mmol/L; n-butyrate: 40 mmol/L) administered twice a day for 14 days (group 1; n = 7)
Study: 2796619
Drug: Tetracaine 10
Normalized name: tetracaine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 10 mg in 10% glucose solution 2 mL + 15 microgram clonidine (Gr.2)
Study: 2796619
Drug: Tetracaine 10
Normalized name: tetracaine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 10 mg in 10% glucose solution 2 mL + 30 microgram clonidine (Gr.3)
Study: 2796619
Drug: Tetracaine 10
Normalized name: tetracaine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 10 mg in 10% glucose solution 2 mL + 45 microgram clonidine (Gr.4)
Study: 2796619
Drug: Tetracaine 10
Normalized name: tetracaine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 10 mg in 10% glucose solution 2 mL (Control Group)
Study: 31761541
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) with a dose prescription of 40 Gy in 5 fractions.
Study: 31761541
Drug: Standardized dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized dose constraints and clinical target volume delineation for SBRT.
Study: 23349295
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in a specialised out‐patient mood disorder clinic
Study: 23349295
Drug: Standard out-patient
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard out-patient treatment
Study: 19487105
Drug: Salmon (150g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon (150g three times per week, resulting in a daily consumption of 2.1g of omega-3 long-chain polyunsaturated fatty acids)
Study: 19487105
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (1.3g of omega-3 long-chain polyunsaturated fatty acids per day)
Study: 19487105
Drug: Cod (150g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod (150g three times per week, resulting in a daily consumption of 0.3g of omega-3 long-chain polyunsaturated fatty acids)
Study: 8698447
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine (10 to 40 mg/d), with possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12.5 to 25 mg/d)
Study: 1470824
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone administered intra‐vaginally (600 mg/d)
Study: 1470824
Drug: Progesterone in
Normalized name: Progesterone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone in solution in oil (50 mg/day) administered by intramuscular injection
Study: 6362694
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine with adrenaline 5 micrograms ml‐1
Study: 6362694
Drug: 1.5% etidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% etidocaine with adrenaline 5 micrograms ml‐1
Study: 26657213
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy sessions (placebo control)
Study: 24674576
Drug: Bifocal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifocal treatment (+1.75 add) during the 3-year period in childhood
Study: 24674576
Drug: Watching television
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watching television <3 hours daily
Study: 22527106
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus patient support program
Study: 20357369
Drug: 0.25 microg
Normalized name: calcitriol 0.25 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 microg 1,25(OH)(2)D(3) daily for 9 months
Study: 18556967
Drug: Compensated Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compensated Insulin Resistance (CIR)
Study: 18556967
Drug: Decompensated Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decompensated Insulin Resistance (DIR)
Study: 18556967
Drug: Normal Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal Insulin Sensitivity (NIS)
Study: 25603459
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg/d)
Study: 15883215
Drug: Glimepiride (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (2.7 mg/d)
Study: 11817924
Drug: Demographic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demographic and psychosocial factors (e.g., race, academic rank, depressive symptomatology, self-reported value of health, appearance, and achievement, parenting style)
Study: 8963917
Drug: Daily ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of 30 mg of beta-carotene supplements
Study: 1704989
Drug: Metoprolol (M)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (M) 100 mg daily
Study: 1704989
Drug: Cilazapril (C)
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (C) 2.5 mg daily
Study: 23326865
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg)
Study: 23420622
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy for personality disorders (CBTpd) plus Treatment as Usual
Study: 21848799
Drug: Esomeprazole (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (7 weeks treatment)
Study: 21848799
Drug: Placebo (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (7 weeks treatment)
Study: 20008236
Drug: Emerging new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging new treatment modalities under investigation for relapsed classical Hodgkin lymphoma
Study: 16973256
Drug: Gosereline (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gosereline (3.6 mg subcutaneous injection monthly)
Study: 11438317
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg daily per os)
Study: 11440901
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 6 mg x kg(‐1) x min(‐1) for 180 min
Study: 11440901
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose infusion at 6 mg x kg(‐1) x min(‐1) for 180 min
Study: 11440901
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of id and iv glucose infusion
Study: 8000630
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac sodium (Voltarol; Ciba‐Geigy)
Study: 30663184
Drug: Clotrimazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (100 mg vaginal tablet, once daily for 7 days)
Study: 30663184
Drug: Salvia officinalis
Normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia officinalis (400 mg vaginal tablet, once daily for 7 days)
Study: 30663184
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Salvia officinalis and Clotrimazole (once daily for 7 days)
Study: 17907482
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride solution (Nupro Neutral)
Study: 10943871
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate, cyclosporin A, and corticosteroids)
Study: 2461826
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of adenosine 5'-monophosphate (AMP) at the provocation concentration required to produce a 20% fall in FEV1 (PC20)
Study: 2461826
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 0.9% (w/v) sodium chloride placebo
Study: 2461826
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of the PC20 allergen
Study: 25641932
Drug: Dry bean
Normalized name: Bean
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry bean enriched diet (250 g/day) for 4 weeks
Study: 25641932
Drug: Self-reported high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported high dry bean intake (≥42 g/day)
Study: 25641932
Drug: Self-reported low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported low dry bean consumption (<8 g/day)
Study: 19358978
Drug: Chronotherapeutic augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronotherapeutic augmentation (CAT; Sleep Deprivation + Bright Light + Sleep Phase Advance)
Study: 19358978
Drug: Medication-only (MED)
Normalized name: CALCIUM 0.8 ORAL TABLET [OnlyCal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-only (MED) group
Study: 11716099
Drug: Paromomycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin plus methylbenzethonium chloride ointment applied twice a day for 20 days
Study: 11716099
Drug: Paromomycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin plus methylbenzethonium chloride ointment
Study: 30648920
Drug: Mobile wellness
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile wellness intervention with Fitbit, daily motivational text messaging, and biweekly counseling for 12 weeks
Study: 7595905
Drug: Losartan monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan monotherapy
Study: 9577009
Drug: Tolperisone HCL
Normalized name: tolperisone HCl
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolperisone HCL (Mydocalm) 150 mg twice daily for 12 weeks
Study: 8449072
Drug: Buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (10 to 20 mg given three times a day)
Study: 27284930
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) 10 mg orally
Study: 24752831
Drug: Hyzetimibe (HS-25)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyzetimibe (HS-25) 10 mg once daily for 10 days
Study: 24752831
Drug: Hyzetimibe (HS-25)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyzetimibe (HS-25) 5, 10, and 20 mg (multiple ascending doses)
Study: 24752831
Drug: Hyzetimibe (HS-25)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyzetimibe (HS-25) 1, 3, 5, 10, 20, and 30 mg (single ascending doses)
Study: 22345094
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg once daily added to losartan 100 mg once daily plus optimal antihypertensive therapy
Study: 22345094
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to losartan 100 mg once daily plus optimal antihypertensive therapy
Study: 11923490
Drug: Undiluted smallpox
Normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undiluted smallpox vaccine (10^8.1 pfu/ml)
Study: 11923490
Drug: 1:5 diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:5 diluted smallpox vaccine (10^7.2 pfu/ml)
Study: 11923490
Drug: 1:10 diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:10 diluted smallpox vaccine (10^7.0 pfu/ml)
Study: 11923490
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (undiluted and diluted vaccines)
Study: 6209832
Drug: Hemodilution therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution therapy
Study: 126848
Drug: Azapropazone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azapropazone (300 mg, 4-times daily)
Study: 126848
Drug: Ketoprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (50 mg, 4-times daily)
Study: 20179636
Drug: Oral beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beclomethasone dipropionate (BDP) 5 mg/day for 8 weeks
Study: 20179636
Drug: Oral 5-aminosalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-aminosalicylate (5‐ASA) 80 mg/kg/day
Study: 17394636
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and activation program (EAP) administered by trained GPs.
Study: 17394636
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) administered by GPs.
Study: 7836337
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg once daily, titrated to a maximum of 200 mg)
Study: 30729333
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D vaginal suppositories
Study: 30729333
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E vaginal suppositories
Study: 23824645
Drug: capecitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: capecitabine (1,000 mg/m2 twice daily, day 1-day 14)
Study: 368299
Drug: Dexamethasone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.3 mg/kg at admission and a similar dose 2 hours later)
Study: 11095456
Drug: Oxandrolone treatment
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone treatment
Study: 19589901
Drug: High intermittent
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intermittent dose of liposomal amphotericin B (10 mg kg(‐1) on day 1, 5 mg kg(‐1) on days 3 and 6)
Study: 19589901
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily dose of liposomal amphotericin B (3 mg kg(‐1) per day for 14 days)
Study: 19589901
Drug: High intermittent
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intermittent dose of liposomal amphotericin B
Study: 19589901
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily dose of liposomal amphotericin B
Study: 17116219
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1000 mg (500 mg bid.) on the first treatment day, increased to 2000 mg (1000 mg bid.) from the second day onward.
Study: 15589082
Drug: Self-care management
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-care management strategies including prescribed medications for pain management (54.21% of participants used this strategy).
Study: 11733289
Drug: BiPAP ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiPAP ventilation plus standard treatment
Study: 11733289
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (non-BiPAP)
Study: 9164221
Drug: Higher-dose chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose chemotherapy regimen with rhGM-CSF (cyclophosphamide 1,800 mg/m2, 4'-epidoxorubicin 60 mg/m2, etoposide 330 mg/m2, cisplatin 120 mg/m2, plus rhGM-CSF 5 micrograms/kg daily for 10 days)
Study: 9164221
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy regimen (cyclophosphamide 1,200 mg/m2, 4'-epidoxorubicin 40 mg/m2, etoposide 225 mg/m2, cisplatin 100 mg/m2)
Study: 9164221
Drug: Higher-dose plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose plus rhGM-CSF group
Study: 2221511
Drug: Chloropromazine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloropromazine 12.5 mg IV (max 37.5 mg)
Study: 2221511
Drug: Dihydroergotamine 1
Normalized name: DIHYDROERGOTAMINE 1MG/ML INJ AMP 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine 1 mg IV (repeated after 30 minutes if inadequate response)
Study: 2221511
Drug: Lidocaine 50
Normalized name: lidocaine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 50 mg IV (max total dose of 150 mg)
Study: 589919
Drug: Chocolate-Sorbitol preparation
Normalized name: chocolate hind preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chocolate-Sorbitol preparation
Study: 589919
Drug: 46 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 46 g of milk chocolate